Extended Group Written Exposure Therapy for Comorbid PTSD and BPD (Traits)
2026년 5월 4일 업데이트: Jennifer Ip, St. Joseph's Healthcare Hamilton
The goal of this open label trial is to evaluate the effectiveness of virtual group extended Written Exposure Therapy (GE-WET) in reducing Post-Traumatic Stress Disorder (PTSD) symptoms in patients with comorbid PTSD and Borderline Personality Disorder (BPD) or BPD traits. GE-WET involves attending weekly 2-hour group WET sessions for the duration of 10 weeks, in which they write about their trauma experience using specific instructions.
This study will be conducted at St. Joseph's Healthcare Hamilton's Community Psychiatry Clinic with clients wait listed for PTSD treatment (ages 18- 65, any gender, co-morbid PTSD and BPD/BPD traits).
The main questions this study aims to answer are:
Does GE-WET reduce PTSD symptoms (based on PCL-5 measures) in this population (outpatient clients ages 18-65 of any gender, with a diagnosis of PTSD and BPD or BPD traits)?
Does GE-WET result in reduced drop-out rates for this population, compared to that of other evidence-based treatment for PTSD?
What are participants subjective experience of GE-WET?
연구 개요
연구 유형
중재적
등록 (추정된)
63
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Ontario
-
Hamilton, Ontario, 캐나다
- St. Joseph's Healthcare Hamilton
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Reading and writing proficiency in English
- Access to an electronic device to attend virtual group meetings
- Age 18-65
- Previous diagnosis of Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD)/BPD traits
- Completion of a DBT skills group via St. Joe's Community Psychiatry Clinic
Exclusion Criteria:
- Diagnosis of an active severe substance use disorder or psychotic disorder
- Untreated active psychotic symptoms, mania, or hypomania
- Has attempted suicide in the 2 months prior to treatment beginning
- Has engaged in high-risk self-harm (e.g., cutting, burning, asphyxiation) in the 2 months prior to beginning treatment
- Has completed Cognitive Processing Therapy or another active PTSD treatment (i.e., prolonged exposure) in the past year
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Group Extended Written Exposure Therapy
Participants will be invited to participate in group extended Written Exposure Therapy (described in the Interventions section).
|
Group Extended Written Exposure Therapy (GE-WET) is a time-limited cognitive behavioural therapy for Posttraumatic Stress Disorder (PTSD) aimed at allowing patients to process their traumatic experiences in a safe environment.
GE-WET will consist of 10 weekly group sessions.
Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience.
The written exposure will be followed by a guided discussion about the experience of writing the exposure.
There is no homework assigned between sessions.
However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
PTSD Checklist for DSM-5 (PCL-5)
기간: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Posttraumatic Cognitions Inventory
기간: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
A 36-item self-report questionnaire that assesses negative thoughts across three subscales: negative cognitions about the self (e.g., "I am a weak person"), negative cognitions about the world (e.g., "I have to be on guard all the time"), and self-blame (e.g., "the event happened because of the way I acted").
The PTCI has demonstrated good internal consistency, test-retest reliability, and convergent validity with other measures of posttraumatic cognitions.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Borderline Symptom List- Short Version (BSL-23)
기간: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The BSL-23 is a 23-item self-report measure that assesses for DSM borderline personality disorder symptomatology as well as associated problems such as self-criticism, loneliness, helplessness, and problems with trust.
The BSL-23 has demonstrated high internal consistency and test-retest reliability, and strong convergent validity with correlations with depression and general psychopathology severity.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Borderline Symptom List Behaviour Supplement
기간: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The BSL-23 Behaviour Supplement is an 11-item supplemental measure used to assess frequency of problematic behaviours (e.g., non-suicidal self-injury, suicide attempts, suicidal communication, angry outbursts, misuse of substances, etc.) associated with borderline personality disorder.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Toronto Alexithymia Scale-20 (TAS-20)
기간: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The TAS-20 is a 20-item self-report measure assessing for alexithymia (i.e., issues in identifying and processing emotions) across three factors: difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking.
The TAS-20 has demonstrated adequate levels of convergent validity, good internal consistency, and good test-retest reliability.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Experience of Shame Scale (ESS)
기간: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The ESS is a 25-item self-report measure assessing characterological shame (e.g., shame of personal habits or personal ability), behavioural shame (e.g., shame in doing or saying something wrong), and bodily shame (e.g., shame regarding one's body).
The ESS has demonstrated good internal consistency and test-retest reliability.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Difficulties in Emotion Regulation Scale (DERS)
기간: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The DERS is a widely used 36-item self-report measure assessing six dimensions of emotion regulation difficulties.
The DERS demonstrates good internal consistency, convergent validity, and predictive validity of behaviours reflective of emotion regulation difficulties.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Group Cohesion Scale - Revised (GCS-R)
기간: Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)
|
The GCS-R is a self-report measure that measure's group member's perception of their group and the strength of the bonds formed.
The GCS-R showed high reliability for use in research and is sensitive to detecting changes in cohesiveness as a function of group development.
|
Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
일반 간행물
- Bagby RM, Taylor GJ, Parker JD. The Twenty-item Toronto Alexithymia Scale--II. Convergent, discriminant, and concurrent validity. J Psychosom Res. 1994 Jan;38(1):33-40. doi: 10.1016/0022-3999(94)90006-x.
- Gratz, K. L., & Roemer, L. (2004). Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. Journal of Psychopathology and Behavioral Assessment, 26, 41-54.
- Foa, E.B., Ehlers, A., Clark, D.M., Tolin, D.F., & Orsillo, S.M. (1999). The Posttraumatic Cognitions Inventory (PTCI): Development and validation. Psychological Assessment, 11(3), 303-314.
- Treadwell, T., Lavertue, N., Kumar, V. K., & Veeraraghavan, V. (2001). The Group Cohesion Scale-Revised: Reliability and validity. International Journal of Action Methods: Psychodrama, Skill Training, and Role Playing, 54(1), 3-12.
- Andrews B, Qian M, Valentine JD. Predicting depressive symptoms with a new measure of shame: The Experience of Shame Scale. Br J Clin Psychol. 2002 Mar;41(Pt 1):29-42. doi: 10.1348/014466502163778.
- Bohus M, Kleindienst N, Limberger MF, Stieglitz RD, Domsalla M, Chapman AL, Steil R, Philipsen A, Wolf M. The short version of the Borderline Symptom List (BSL-23): development and initial data on psychometric properties. Psychopathology. 2009;42(1):32-9. doi: 10.1159/000173701. Epub 2008 Nov 20.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 6월 1일
기본 완료 (추정된)
2028년 6월 1일
연구 완료 (추정된)
2028년 12월 1일
연구 등록 날짜
최초 제출
2026년 4월 20일
QC 기준을 충족하는 최초 제출
2026년 5월 4일
처음 게시됨 (실제)
2026년 5월 8일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 5월 8일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 5월 4일
마지막으로 확인됨
2026년 5월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 18906
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Group Written Exposure Therapy에 대한 임상 시험
-
Chinese PLA General HospitalJiangsu Hansoh Pharmaceutical Co., Ltd.모병투석; 합병증 | 만성 신장 질환 5D | 만성 신장 질환의 신장 빈혈 | 신장 빈혈 | 신장 빈혈, 만성중국